Compare Msci Inc (MSCI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Msci Inc trades at $562.19 (market cap $40.38B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.2× Msci Inc's market cap, and Msci Inc pays a 1.48% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MSCI | VRTX | |
|---|---|---|
Market Cap | $40.38B | $128.16B |
Volume | 414,140 | 806,603 |
Sector | Financials | Health |
52-Week High | $643.83 | $557.96 |
52-Week Low | $511.84 | $407.37 |
Typical Hold Time | 82 Days | 120 Days |
Enterprise Value | $46.54B | $122.29B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $555.38, up 0.08% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $3.13B and net income margin of 40.73%. Recent Q2 2026 earnings slightly missed expectations at $4.94 EPS versus $4.99 expected, though Q1 and Q4 2025 beat estimates. Analyst consensus remains strongly bullish with 74% buy ratings and $701.71 price target, representing 26% upside potential. The stock shows consistent revenue growth from $2.2B in 2022 to $3.1B in 2025.
MSCI presents a compelling investment case with premium valuation (P/E 30.37) justified by strong profitability and market leadership. Key risks include high debt levels ($4.51B long-term debt) and competitive pressures in financial data services. The upcoming Q3 2026 earnings report on October 20, 2026, will be crucial for validating growth trajectory. Institutional sentiment remains positive given the company's recurring revenue model and expansion into climate risk analytics through the First Street acquisition.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
